{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:03:00Z","timestamp":1784808180391,"version":"3.55.0"},"reference-count":74,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/501100000308","name":"British Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011326","name":"London School of Economics and Political Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"United Kingdom Research and Innovation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Global Public Health"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/17441692.2026.2708415","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:20:56Z","timestamp":1784805656000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Increasing competition in pharmaceutical tenders: Patents, treatment guidelines, and centralised procurement of Hepatitis C drugs in Brazil"],"prefix":"10.1080","volume":"21","author":[{"given":"Eduardo","family":"Mercadante","sequence":"first","affiliation":[{"name":"Department of International Development, London School of Economics and Political Science (LSE)","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"A\u00e7\u00e3o Direta de Inconstitucionalidade 5.529. ( 2021). (Supremo Tribunal Federal September 14 2021). https:\/\/portal.stf.jus.br\/processos\/detalhe.asp?incidente=4984195"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/17441692.2024.2350654"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/1043859042000188692"},{"key":"e_1_3_4_5_1","unstructured":"Anvisa \u2013 National Health Surveillance Agency. ( 2022). Resolu\u00e7\u00e3o da Diretoria Colegiada No 753 https:\/\/www.in.gov.br\/web\/dou\/-\/resolucao-rdc-n-753-de-28-de-setembro-de-2022-433925794"},{"key":"e_1_3_4_6_1","unstructured":"Anvisa \u2013 National Health Surveillance Agency. ( 2024). Consultas: Medicamentos [Data set]. Retrieved August 9 2024 from https:\/\/consultas.Anvisa.gov.br\/#\/medicamentos\/"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.09.024"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1787\/413f2820-en"},{"key":"e_1_3_4_9_1","unstructured":"BCB \u2013 Brazilian Central Bank. ( 2024). Cota\u00e7\u00f5es e boletins [Data set]. https:\/\/www.BCB.gov.br\/estabilidadefinanceira\/historicocotacoes"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2019.04.010"},{"key":"e_1_3_4_11_1","unstructured":"Bermudez J. (2018). Patente: Sofosbuvir entre o com\u00e9rcio e o direito \u00e0 cura. Fiocruz \u2013 Funda\u00e7\u00e3o Oswaldo Cruz. https:\/\/cee.fiocruz.br\/?q=Patente-sofosbuvir-entre-o-com%C3%A9rcio-e-o-direito-%C3%A0-cura%E2%80%93por-Jorge-Bermudez"},{"key":"e_1_3_4_12_1","volume-title":"Tackling the Triple Transition in Global Health Procurement","author":"Bonnifield R.","year":"2019","unstructured":"Bonnifield, R. , Madan Keller, J. , Glassman, A. , & Chalkidou, K. (2019). Tackling the Triple Transition in Global Health Procurement . Center for Global Development. https:\/\/www.cgdev.org\/better-health-procurement"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/03085147.2022.1987752"},{"key":"e_1_3_4_14_1","unstructured":"Brazil. ( 2024a). Portal da Transpar\u00eancia \u2013 Detalhamento das Licita\u00e7\u00f5es [Data set]. Retrieved September 4 2024 from https:\/\/portaldatransparencia.gov.br\/licitacoes\/consulta"},{"key":"e_1_3_4_15_1","unstructured":"Brazil. ( 2024b). Portal de Compras do Governo Federal [Data set]. Retrieved September 4 2024 from http:\/\/comprasnet.gov.br\/acesso.asp?url=\/livre\/pregao\/ata0.asp"},{"key":"e_1_3_4_16_1","unstructured":"CADE \u2013 Administrative Council for Economic Defense. ( 2022). Nota T\u00e9cnica no 15\/2022\/CGAA11\/SG\/CADE. https:\/\/sei.CADE.gov.br\/sei\/modulos\/pesquisa\/md_pesq_documento_consulta_externa.php?HJ7F4wnIPj2Y8B7Bj80h1lskjh7ohC8yMfhLoDBLddYaLyDHLsXw8i3Jmr4Ix_8YWVJ4Y8xvXN-vmAYxv2lIKIiLKQrc8RqqB2XM-wxAjpUkKIaRKhCN8iQgzvkR-cSH"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.33448\/rsd-v11i15.37584"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-76834-2"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1590\/1413-81232017228.05602017"},{"key":"e_1_3_4_20_1","unstructured":"Davidian A. & Fonseca E. (2022). Enfrentamento \u00e0 Hepatite C no Brasil: Vigil\u00e2ncia Controle e Assist\u00eancia. https:\/\/repositorio.fgv.br\/server\/api\/core\/bitstreams\/a5fc0685-9b30-43e8-a219-b78ab13e44d1\/content"},{"key":"e_1_3_4_21_1","unstructured":"DNDi \u2013 Drugs for Neglected Diseases Initiative. ( 2024). Ravidasvir + sofosbuvir. https:\/\/dndi.org\/research-development\/portfolio\/ravidasvir-sofosbuvir\/"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1162-z"},{"key":"e_1_3_4_23_1","unstructured":"FDA \u2013 Food and Drug Administration. ( 2023). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations [Data set]. Retrieved August 9 2023 from https:\/\/www.accessdata.FDA.gov\/scripts\/cder\/ob\/index.cfm"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1590\/s0104-12902024220791en"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckaf245"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordhb\/9780199286805.003.0010"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-76834-2_7"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.2075"},{"key":"e_1_3_4_29_1","unstructured":"IBGE \u2013 Brazilian Institute of Geography and Statistics. ( 2023). \u00cdndice Nacional de Pre\u00e7os ao Consumidor Amplo \u2013 IPCA [Data set]. https:\/\/sidra.IBGE.gov.br\/pesquisa\/snipc\/ipca\/tabelas"},{"key":"e_1_3_4_30_1","unstructured":"INPI \u2013 National Institute of Industrial Property. ( 2019). Situa\u00e7\u00e3o dos pedidos de patente com exame priorit\u00e1rio por solicita\u00e7\u00e3o do Minist\u00e9rio da Sa\u00fade. https:\/\/www.gov.br\/INPI\/pt-br\/servicos\/patentes\/tramite-prioritario\/Documentos\/SituaoPrioritriosSadeJulho2019.pdf"},{"key":"e_1_3_4_31_1","unstructured":"INPI \u2013 National Institute of Industrial Property. ( 2024). pePI \u2013 Pesquisa em Propriedade Industrial [Data set]. Retrieved November 9 2024 from https:\/\/busca.INPI.gov.br\/pePI\/"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-lawsocsci-110316-113303"},{"key":"e_1_3_4_33_1","unstructured":"Long\u00ednio dos Santos M. (2023). Fiocruz assina acordo para registro de medicamento para hepatite C na Anvisa. Fiocruz \u2013 Funda\u00e7\u00e3o Oswaldo Cruz. https:\/\/Fiocruz.br\/noticia\/2023\/07\/Fiocruz-assina-acordo-para-registro-de-medicamento-para-hepatite-c-na-anvisa"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2019.08.001"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-018-0405-7"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2018.00007"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jwip.70018"},{"key":"e_1_3_4_38_1","unstructured":"MoH \u2013 Ministry of Health. ( 2011). Protocolo cl\u00ednico e diretrizes terap\u00eauticas para Hepatite C e coinfec\u00e7\u00f5es. https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/protocolo_clinico_diretrizes_hepatite_co_coinfeccoes.pdf"},{"key":"e_1_3_4_39_1","unstructured":"MoH \u2013 Ministry of Health. ( 2015). Protocolo cl\u00ednico e diretrizes terap\u00eauticas para Hepatite C e coinfec\u00e7\u00f5es. https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/protocolo_clinico_diretrizes_hepatite_co_coinfeccoes.pdf"},{"key":"e_1_3_4_40_1","unstructured":"MoH \u2013 Ministry of Health. ( 2017). Protocolo cl\u00ednico e diretrizes terap\u00eauticas para Hepatite C e coinfec\u00e7\u00f5es. https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/protocolo_clinico_diretrizes_terapeuticas_hepatite_c_coinfeccoes.pdf"},{"key":"e_1_3_4_41_1","unstructured":"MoH \u2013 Ministry of Health. ( 2019). Protocolo cl\u00ednico e diretrizes terap\u00eauticas para Hepatite C e coinfec\u00e7\u00f5es. https:\/\/www.gov.br\/saude\/pt-br\/assuntos\/saude-de-a-a-z\/h\/hepatites-virais\/publicacoes\/protocolo-clinico-e-diretrizes-terapeuticas-para-hepatite-c\/view"},{"key":"e_1_3_4_42_1","unstructured":"MoH \u2013 Ministry of Health. ( 2022a). Of\u00edcio Circular No 6\/2022\/CGAHV\/.DCCI\/SVS\/MS. https:\/\/antigo.aids.gov.br\/pt-br\/legislacao\/oficio-circular-no-62022cgahvdccisvsms"},{"key":"e_1_3_4_43_1","unstructured":"MoH \u2013 Ministry of Health. ( 2022b). Portaria No 163 SCTIE\/MS. https:\/\/www.gov.br\/conitec\/pt-br\/midias\/relatorios\/portaria\/2022\/20221202_portaria_sctie_ms_n163.pdf"},{"key":"e_1_3_4_44_1","unstructured":"MoH \u2013 Ministry of Health. ( 2023). Nota T\u00e9cnica No 280\/2023-CGAHV\/.DATHI\/SVSA\/MS. https:\/\/www.gov.br\/aids\/pt-br\/central-de-conteudo\/notas-tecnicas\/2023\/nota-tecnica-no-280_2023-revoga-nt-30_2023.pdf"},{"key":"e_1_3_4_45_1","unstructured":"MoH \u2013 Ministry of Health. ( 2024a). Boletim Epidemiol\u00f3gico: Hepatites Virais 2024. https:\/\/www.gov.br\/aids\/pt-br\/central-de-conteudo\/boletins-epidemiologicos\/2024\/boletim-epidemiologico-hepatites-virais-2024"},{"key":"e_1_3_4_46_1","unstructured":"MoH \u2013 Ministry of Health. ( 2024b). Parcerias para o Desenvolvimento Produtivo \u2013 PDP [Data set]. https:\/\/www.gov.br\/saude\/pt-br\/composicao\/sectics\/pdp"},{"key":"e_1_3_4_47_1","unstructured":"MPP \u2013 Medicines Patent Pool. ( 2020). Affordable versions of Hepatitis C medicine daclatasvir soon available in additional countries. https:\/\/medicinespatentpool.org\/news-publications-post\/affordable-versions-of-hepatitis-c-medicine-daclatasvir-soon-available-in-additional-countries"},{"key":"e_1_3_4_48_1","unstructured":"MPP \u2013 Medicines Patent Pool. ( 2023). Medicines Patent and License Database \u2013 MedsPaL [Data set]. Retrieved August 9 2023. https:\/\/www.medspal.org\/"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-022-00847-z"},{"key":"e_1_3_4_50_1","unstructured":"Pimentel V. (2018). Parcerias para o Desenvolvimento Produtivo de medicamentos no Brasil sob a \u00f3tica das compras p\u00fablicas para inova\u00e7\u00e3o: 2009-2017 [Master\u2019s Dissertation]. Universidade Federal do Rio de Janeiro."},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-83114-1_12"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijindorg.2007.08.004"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.38116\/9786556350806cap8"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-7218(10)01007-5"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2019.05.009"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-83114-1_8"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respol.2017.01.005"},{"key":"e_1_3_4_58_1","unstructured":"Senado Federal. ( 2018). Patente n\u00e3o vai impedir produ\u00e7\u00e3o de gen\u00e9rico do Sofosbuvir diz ministro. https:\/\/www12.senado.leg.br\/noticias\/materias\/2018\/11\/13\/patente-nao-vai-impedir-producao-de-generico-do-sofosbuvir-diz-ministro"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780199593903.001.0001"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-018-0423-0"},{"key":"e_1_3_4_61_1","unstructured":"Souza C. Paranhos J. & Hasenclever L. (2022). A regula\u00e7\u00e3o de pre\u00e7os de medicamentos novos: Aprendizados para o Brasil a partir de casos internacionais. ENAP \u2013 I Pr\u00eamio de Artigos Em Advocacia Da Concorr\u00eancia e Regula\u00e7\u00e3o Econ\u00f4mica. https:\/\/repositorio.enap.gov.br\/bitstream\/1\/7248\/1\/1.1.ID.68-Artigo-reeditorado.pdf"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1590\/1982-3533.2023v32n1art07"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32053"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12714"},{"key":"e_1_3_4_65_1","unstructured":"UNITAID. ( 2015a). Review of the Elbasvir Patent Landscape: A scoping report. http:\/\/www.unitaid.org\/assets\/Elbasvir_Patent_Landscape.pdf"},{"key":"e_1_3_4_66_1","unstructured":"UNITAID. ( 2015b). Review of the Grazoprevir Patent Landscape: A scoping report. https:\/\/unitaid.org\/assets\/Grazoprevir_Patent_Landscape.pdf"},{"key":"e_1_3_4_67_1","unstructured":"UNITAID. ( 2017a). Review of the Glecaprevir Patent Landscape: A scoping report. https:\/\/unitaid.org\/assets\/Glecaprevir_patent-landscape_March2017.pdf"},{"key":"e_1_3_4_68_1","unstructured":"UNITAID. ( 2017b). Review of the Pibrentasvir Patent Landscape: A scoping report. https:\/\/unitaid.org\/assets\/Pibrentasvir_patent-landscape_March2017.pdf"},{"key":"e_1_3_4_69_1","unstructured":"UNITAID. ( 2017c). Review of the Velpatasvir Patent Landscape: A scoping report. http:\/\/www.unitaid.org\/assets\/Velpatasvir_Patent_Landscape.pdf"},{"key":"e_1_3_4_70_1","unstructured":"Vieira F. S. (2020). Direito \u00e0 Sa\u00fade no Brasil: Seus contornos judicializa\u00e7\u00e3o e a necessidade da macrojusti\u00e7a. https:\/\/repositorio.ipea.gov.br\/handle\/11058\/9714"},{"key":"e_1_3_4_71_1","unstructured":"WHO \u2013 World Health Organization. ( 2016). WHO updates patent information on treatments for Hepatitis C. https:\/\/www.WHO.int\/news\/item\/19-07-2016-WHO-updates-patent-information-on-treatments-for-hepatitis-c"},{"key":"e_1_3_4_72_1","unstructured":"WHO \u2013 World Health Organization. ( 2024). Global hepatitis report 2024: Action for access in low- and middle-income countries. https:\/\/www.WHO.int\/publications\/i\/item\/9789240091672"},{"key":"e_1_3_4_73_1","unstructured":"WHS \u2013 World Hepatitis Summit. ( 2017). Accelerating action towards the elimination of viral hepatitis \u2013 World Hepatitis Summit 2017 Event Report. https:\/\/worldhepatitissummit.org\/world-hepatitis-summit-2017\/"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2018.11.029"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.12.007"}],"container-title":["Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17441692.2026.2708415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17441692.2026.2708415","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17441692.2026.2708415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:22:45Z","timestamp":1784805765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17441692.2026.2708415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/17441692.2026.2708415"],"URL":"https:\/\/doi.org\/10.1080\/17441692.2026.2708415","relation":{},"ISSN":["1744-1692","1744-1706"],"issn-type":[{"value":"1744-1692","type":"print"},{"value":"1744-1706","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=rgph20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=rgph20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2708415"}}